Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 1, 2005. The report details changes in directors' interests in the company's Ordinary Shares and American Depository Shares (ADSs) resulting from share allocation arrangements for non-executive directors for the service period of January 1 to March 31, 2005.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is limited to corporate governance disclosures regarding director share allocations.
Material Changes
On March 31, 2005, non-executive directors were provisionally allocated awards under the company's share allocation arrangements. The specific allocations are as follows:
- Sir Christopher Gent: 2,054.23 Ordinary Shares
- Mr Lawrence Culp: 595.04 ADSs
- Sir Crispin Davis: 1,643.39 Ordinary Shares
- Sir Deryck Maughan: 595.04 ADSs
- Sir Ian Prosser: 1,129.83 Ordinary Shares
- Dr Ronaldo Schmitz: 903.86 Ordinary Shares
- Dr Lucy Shapiro: 148.76 Ordinary Shares
- Sir Robert Wilson: 513.56 Ordinary Shares
The Company and directors were informed of these allocations on April 1, 2005.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Investor Verification Points
- Verify the final vesting status of the provisional share allocations listed for non-executive directors.
- Confirm the total number of Ordinary Shares and ADSs held by each director following this allocation.
- Review the specific terms of the share allocation arrangements for non-executive directors for the period of January 1 to March 31, 2005.